Lessina may be part of symptomatic management for fertility, generally for women seeking a routine, ongoing option for birth control. This medication is applied within the therapeutic domain of Reproductive Health and Fertility Regulation and is considered relevant for preventing the medical condition of unintended pregnancy. The combination of active ingredients is commonly used to help with the prevention of pregnancy.

Reliable Prevention of Unintended Pregnancy

This therapeutic domain covers the core function of the medication—establishing a continuous state of contraceptive assurance. Lessina may be applied when the patient seeks long-term, routine support to assist with the control of conception, addressing the patient's need for personal planning. The medication contributes to the prevention of pregnancy during routine, consistent daily use.

Support for Reproductive Management

Lessina is commonly used in clinical scenarios requiring chronic, routine hormonal support. Its use supports general well-being during management and may assist with maintaining functional stability by providing a reversible method for fertility regulation.

Quick Fact: Primary Therapeutic Benefit
Fertility Control: Contributes to the prevention of pregnancy during routine, consistent daily use.

Regulatory References

1. DailyMed: Official Labeling for Lessina’s Active Ingredients

Lessina (levonorgestrel/ethinyl estradiol) is an oral contraceptive authorized for use by postpubertal females to prevent pregnancy. Its use is strictly defined by specific contraindications to minimize serious health risks, primarily related to blood clotting, cancer, and liver function.

Contraindicated Populations

Lessina is contraindicated in women who are known to have a high risk of arterial or venous thrombotic diseases. This includes women over age 35 who smoke, and those with a history of stroke, heart attack, deep vein thrombosis, pulmonary embolism, or uncontrolled hypertension. The medication is also prohibited for patients with:

• Current or past history of breast cancer or other hormone-sensitive cancers.
• Liver tumors (benign or malignant) or active liver disease, such as severe decompensated cirrhosis or acute viral hepatitis.
• Migraine headaches with aura, or any migraine headaches if the user is over age 35.
• Known or suspected pregnancy or undiagnosed abnormal genital bleeding.

Lessina is generally not indicated for women who are breastfeeding or those who are postmenopausal.

Lessina Interactions with other medicines and products

Official regulatory information outlines several categories of interacting substances and specifies certain combinations that are prohibited.

Contraindicated Combinations

Co-administration is formally contraindicated with the following due to clinically significant risks documented in official labeling:

• Hepatitis C Drug Regimens: Combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, are prohibited due to the risk of serious liver enzyme (ALT) elevations.
• Tranexamic Acid (oral): Contraindicated due to the officially stated risk of increased thromboembolic events.
• Fezolinetant: Contraindicated, as ethinyl estradiol increases its systemic exposure.

---

Other Clinically Significant Interactions

Interaction Type	Interacting Substances/Classes	Practical Regulatory Constraint
Reduced Exposure	Hepatic Enzyme Inducers (e.g., Rifampin, Phenytoin, St. John's wort)	Officially risks diminished contraceptive effectiveness via increased clearance of hormones.
Increased Exposure	CYP Inhibitors (e.g., Grapefruit juice, Itraconazole); Statins (Atorvastatin, Rosuvastatin)	These may raise the systemic concentration of ethinyl estradiol.
Absorption Interference	Colesevelam (Bile acid sequestrant)	Requires a timing separation: Lessina must be administered at least 4 hours before Colesevelam to ensure adequate absorption.
Pharmacodynamic	Lamotrigine (Lessina reduces its exposure)	Lessina induces glucuronidation, officially reducing Lamotrigine plasma levels.

---

Population-Specific Notes

The combination of Lessina and cigarette smoking/tobacco is formally defined as a contraindication for women 35 years of age and older, as this interaction substantially increases the risk of serious cardiovascular events.

How Lessina Works

Lessina, a combination of the synthetic progestin levonorgestrel and the synthetic estrogen ethinyl estradiol, mediates its action primarily through the suppression of the hypothalamic-pituitary-ovarian axis. The hormonal components inhibit the release of Gonadotropin-Releasing Hormone (GnRH) and prevent the midcycle surge of Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH).

This cascade results in the inhibition of ovulation.

Secondary actions involve morphological and biochemical modulation of reproductive tissues. The progestin component increases the viscosity of cervical mucus, thereby mechanically impeding sperm motility and penetration. Concurrently, the steroid hormones induce alterations in the endometrium, reducing its receptivity for blastocyst implantation. The overall mechanism is the sum of these three distinct physiological modulations.

How Lessina is Used

Lessina is administered through the oral route as a 28-day cyclic regimen for continuous, long-term fertility regulation. The official adult dosing regimen is one tablet once daily, following a structure that includes 21 consecutive days of active tablets (Levonorgestrel 0.10 mg / Ethinyl Estradiol 0.02 mg) and 7 consecutive days of inactive, non-hormonal tablets.

---

Administration Protocol

The full 28-day course of tablets must be ingested at the same time each day to maintain a consistent usage pattern. The tablets are taken in the exact order directed on the blister pack to ensure the correct progression from hormonal to non-hormonal components. Initiation of the first cycle generally follows one of two label-based procedures: the First-Day Start (on the first day of the menstrual period) or the Sunday Start (on the first Sunday after the menstrual period begins).

Usage Constraint	Detail
Dose Pattern	21 Active tablets followed by 7 Inactive tablets.
Frequency	Once daily, at the same time each day.
Duration	Continuous, long-term cycles until cessation is desired.

---

The pattern requires an immediate transition to a new 28-day pack upon completion of the previous one. The official label also includes specific procedural instructions for handling missed active tablets, which details the required action depending on the number of pills missed and the specific week of the cycle. The medication is used in postmenarchal females and generally does not carry label-based dose adjustments for renal or hepatic impairment within the standard usage context.

Research Evidence / Overview of Studies for Lessina

Evidence for Use in Preventing Unintended Pregnancy

The primary indication for this formulation was studied for its use in preventing unintended pregnancy. The evidence base includes a variety of rigorous research types, such as Randomized Controlled Trials (RCTs), where this formulation was compared against other combined oral contraceptive (COC) pills, as well as large-scale Systematic Reviews and decades of High-Quality Observational Studies.

These studies monitored the main outcome related to contraceptive effectiveness, which was measured by the Pearl Index (PI)—a standard regulatory metric quantifying the number of unintended pregnancies that was observed in a group of 100 women over one year of use. The findings describe patterns observed in the studies regarding the effectiveness measurement, which is tracked and summarized in the scientific literature.

Research on Cycle Control and Usage Patterns

Research was studied for whether this combination was associated with changes in the menstrual cycle itself. The clinical trials evaluated in women of reproductive age tracked key outcomes related to systemic or functional imbalance. Specifically, studies explored how regularly scheduled bleeding was observed during the placebo phase and monitored any instances of unscheduled bleeding or spotting (breakthrough bleeding) throughout the cycle.

What is Still Uncertain in the Research Landscape

While the research base is large, certain areas of uncertainty and limitation remain. A key limitation the research describes is that the difference between effectiveness under ideal adherence and under typical real-world use data show patterns related to the difficulty of strict daily adherence.

There is limited information for long-term outcomes regarding physiological processes that was observed in the study populations, beyond the scope of its approved use. Also, for women in the high BMI ge 30 kg/m^2 category, research data show patterns related to measured outcomes that was observed in some studies to be different compared to the general study population.

Key Studies & References

1. Levonorgestrel and Ethinyl Estradiol Tablets USP, 0.1 mg/0.02 mg - DailyMed
2. Combined hormonal contraceptive (CHC) use among obese women and contraceptive effectiveness: a systematic review - CDC Stacks
3. Oral Contraceptive Pills - StatPearls - NCBI Bookshelf - NIH

Common questions about Lessina (FAQ)

Q: What is Lessina?

Lessina is a combination oral contraceptive (COC), also known as a birth control pill. It contains two types of female hormones: an estrogen (ethinyl estradiol) and a progestin (levonorgestrel). It is used to prevent pregnancy.

Q: How does Lessina work to prevent pregnancy?

Lessina primarily prevents pregnancy by stopping the release of an egg from the ovary (ovulation). It also works by thickening the cervical mucus, which makes it harder for sperm to reach the egg, and by changing the lining of the uterus (endometrium), making it less suitable for implantation.

Q: What should I do if I miss a dose of Lessina?

Missing a dose increases the risk of pregnancy. What you should do depends on how many pills you missed and where you are in the pack.

• If you miss 1 active pill: Take it as soon as you remember, even if it means taking two pills in one day. Take the rest of the pack as usual. You do not need a backup birth control method.
• If you miss 2 or more active pills in a row: Take the last missed pill as soon as you remember. Throw away any other missed pills. Continue taking the rest of the pack, but use a backup birth control method (like condoms) for the next 7 days. If you miss pills in the last week of active pills, you may need to skip the placebo pills and start a new pack immediately. Always consult your healthcare provider or the detailed patient information leaflet for specific instructions on managing multiple missed doses.

Q: Can Lessina protect me against sexually transmitted infections (STIs)?

No, Lessina does not protect against HIV/AIDS or other sexually transmitted infections (STIs). You must use a condom to reduce the risk of contracting or spreading STIs.

Q: Does Lessina cause weight gain?

Clinical studies on Lessina and similar combination oral contraceptives have yielded mixed results regarding weight changes. Some individuals may experience minor weight fluctuations, but for many, these changes are not significant or sustained. If you are concerned about weight gain, discuss it with your healthcare provider.

Q: Is it normal to have spotting or breakthrough bleeding while taking Lessina?

Yes, irregular bleeding, such as spotting or breakthrough bleeding, is a common side effect, especially during the first few months of starting Lessina. This usually improves as your body adjusts to the hormones. If the bleeding is heavy or continues for several cycles, you should talk to your healthcare provider.

Official Storage and Disposal Requirements

Lessina (levonorgestrel and ethinyl estradiol tablets) must be stored according to specific regulatory conditions to maintain product stability and integrity.

Storage Conditions

The tablets require storage at Controlled Room Temperature (CRT), which ranges from 20°C to 25°C (68°F to 77°F). It is mandatory to keep the medicine from freezing and protect it from excess heat, light, and moisture.

Storage Rule	Requirement
Temperature	20°C to 25°C (CRT)
Protection	Protect from freezing, light, heat, and moisture
Container	Store in the original protective blister or closed container
Safety	Keep out of the reach of children

Disposal Instructions

Outdated or unused medicine should be disposed of in accordance with local requirements. Patients should consult a healthcare professional regarding the proper procedure for discarding the medication.